On November 27, 2018 Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, reported it will host a conference call and live audio webcast on Monday, December 3, 2018 at 9:00 a.m. EST to review the MEDALIST and BELIEVE Phase 3 trial presentations of luspatercept at the 60th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition taking place on December 1-4, 2018 in San Diego, California (Press release, Acceleron Pharma, NOV 27, 2018, View Source [SID1234531644]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Guest Presenters:
Alan F. List, M.D., President and CEO of Moffitt Cancer Center, Senior member in the Department of Malignant Hematology and the Experimental Therapeutics Program, Professor of Internal Medicine and Oncology at the University of South Florida Morsani College of Medicine
Maria Domenica Cappellini, M.D., Chief of the Internal Medicine Unit, Professor of Internal Medicine, University of Milan, Chief of the Rare Disease Centre at the Policlinico Hospital IRCCS Foundation Ca’ Granda, Milan, Italy
Participants can access the live conference call by dialing 877-312-5848 (domestic) or 253-237-1155 (international) and referring to the "Acceleron ASH (Free ASH Whitepaper) 2018 Conference Call."
The live webcast can be accessed under "Events & Presentations" in the Investors/Media page of the company’s website at www.acceleronpharma.com.
A replay of the webcast will be available approximately two hours after the event on the Acceleron website.